Four Mobia Medical Insiders Put Nearly $11 Million of Their Own Money Into the IPO — On the Same Day

🟢 Insider Activity Score: 99/100

A director and 10% owner, two independent directors, and the company's general counsel all purchased shares at the IPO price on the same filing date, collectively deploying nearly $11 million in personal capital into a medical device company on its first day as a public company. This is not a post-IPO dip buy, a secondary offering, or a show of confidence after a rough quarter. This is insiders writing checks alongside the public — at the exact same price.

That almost never happens.

When a company goes public, the standard insider playbook is to not buy more. Executives and directors already hold equity from years of private-stage participation. The IPO is typically where early stakeholders begin thinking about when they can sell — not how much more they want to own. Lock-up periods, blackout windows, and the sheer optics of insider buying at a freshly priced offering make new purchases rare.

Which is what makes May 11, 2026 at Mobia Medical so unusual.

On the day the company's Form 4 filings hit the SEC, four insiders — a director and 10% owner, two independent directors, and the General Counsel — had collectively purchased 727,999 shares at $15.00, the IPO offer price, for a combined $10.93 million. All filed the same day. All at the same price. All in.

The Anchor: William T. Harrington — $8 Million

The lead signal came from William T. Harrington, a director and 10% owner who committed $8 million to purchase 533,333 shares at the $15.00 offer price. At that scale, this isn't a symbolic gesture — it's a cornerstone position. Harrington's deployment of personal capital at the IPO price effectively sets a valuation floor, communicating that someone with deep, long-standing knowledge of this company's financials, pipeline, and competitive position views $15.00 not as a ceiling to sell into, but as a foundation to build on.

For a medical device company entering public markets mid-clinical-scaling, that kind of insider conviction carries real weight.

The Confirmation: Cynthia L. Lucchese — $1.88 Million

Where a single large purchase can be rationalized away, a second one at the identical price point is harder to dismiss. Cynthia L. Lucchese, a director with deep experience in medical device commercialization, purchased 125,000 shares at $15.00 for approximately $1.88 million — independently arriving at the same price, the same timing, and the same directional bet as Harrington.

Lucchese's background in bringing medical devices from development through commercial scale makes her participation particularly notable. This isn't a financial generalist buying on instinct. This is someone who has seen how these pipelines develop, knows what clinical scaling actually looks like operationally, and still decided to write a nearly $2 million check on day one.

The Third Leg: Casey M. Tansey — $1 Million

Casey M. Tansey, a director and Managing Partner at U.S. Venture Partners — the lead investor in Mobia Medical — added $1 million of his own capital to purchase 66,666 shares at the same $15.00 offer price. His participation reframes a critical question that hovers over every venture-backed IPO: is the lead investor here to build, or here to exit?

Tansey's personal purchase answers that directly. When the Managing Partner of the lead VC firm is buying at the offer price alongside the public — not selling, not waiting, not hedging — it signals that the people who know this company's internals best view the IPO valuation as an entry point, not a liquidity event.

Three directors. Three purchases. One price. Zero ambiguity about where the board stands.

The Fourth Leg: Chase C. Leavitt, General Counsel — $45,000

The final filing came from Chase C. Leavitt, Mobia Medical's General Counsel — the officer legally responsible for SEC compliance, disclosure integrity, and the accuracy of every public statement the company makes. His purchase of 3,000 shares at $15.00 totaled $45,000, modest against the director-level commitments but meaningful in what it represents.

General Counsels don't buy stock casually. They live closer to the legal and regulatory realities of a public company than almost any other executive. The fact that Leavitt chose to participate in the same IPO sweep — even at a smaller scale — extends the signal of internal conviction from the boardroom all the way into the executive suite.

When the company's top legal officer puts his own money in alongside the board on day one, that's an "all-in" culture that goes deeper than a press release.

About Mobia Medical

Mobia Medical, Inc. is a medical device company that debuted on the Nasdaq in a $150 million IPO priced at $15.00 per share. The company is focused on the clinical scaling of its Vivistim system — a neurostimulation platform designed to support stroke recovery. Mobia operates in a high-conviction corner of the medical device space, where clinical evidence and regulatory milestones drive valuation, and where the gap between early-stage promise and commercial execution is where most companies are won or lost.

How to Think About This

Insider buying at IPO is rare. Coordinated, board-wide insider buying at IPO — across four separate individuals, at the same price, filed on the same day — is exceptional. But before treating this as an unqualified green light, two structural realities deserve honest acknowledgment.

First, the mechanics. Many IPOs include what's known as a Directed Share Program — a reserved share arrangement, typically organized by the underwriters, that allows insiders and select participants to purchase at the offer price. When that structure exists, these transactions are less "spontaneous conviction" and more "organized support." They still represent real money from real people who could have declined to participate. But they aren't the same as an executive independently picking up the phone and placing a buy order. Whether Mobia's IPO included a DSP hasn't been confirmed in public disclosures, and it's a question worth asking before drawing firm conclusions from the coordination alone.

Second, proportionality. Eight million dollars is a large number in isolation. Whether it's a "bet the farm" commitment or a strategic position to support the offering depends entirely on what William Harrington's broader balance sheet looks like — and that's information no Form 4 provides. The same logic applies to each of the four buyers. Dollar size tells you what happened. It doesn't tell you what it cost them.

Neither of these points negates the signal. Four insiders, one price, one day, nearly $11 million in combined personal capital — that pattern is still unusual and still worth your attention. What it does mean is that the full picture requires a bit more digging than the filings alone can provide.

That's true of most signals worth following.

Consolidated Insider Filings: Mobia Medical SEC Index

The IPO Prospectus: Form 424B4

Market Munchies and Mode Mobile communications are for informational purposes only, and are not a recommendation, solicitation, or research report relating to any investment strategy, security, or digital asset. All investments involve risk including the loss of principal and past performance does not guarantee future results.

Any information contained in this commentary does not purport to be a complete description of the securities, markets, or developments referred to in this material. The information has been obtained from sources considered to be reliable, but we do not guarantee that the foregoing material is accurate or complete. There is no guarantee that any statements or opinions provided herein will prove to be correct.